Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017

Report Overview

Table of Contents

2235.34

Select License Type

£2,235.35	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£4,470.69	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£6,706.04	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£2,235.35	Add to Wishlist
Change Currency	GBP EURO USD
	Order By Fax

Market	Healthcare and Medical
Report Type	Market Research
Country	Global
Published	1 February 2012
Number of Pages	290
Report Delivery	Email
Delivery Lead Time	1-3 hours, 24 hour max
Publisher	GBI Research
File Format	PDF

Immunosuppressants hold a 64% market share of the immunomodulators market

Immunosuppressants generated revenues of $92.2 billion in 2010 while immunostimulants generated revenues of $53.7 billion. There are more classes of immunosuppressants than immunostimulants because it is difficult to boost the cells of the immune system as they all respond to antigens in different ways. The immunostimulants market is estimated to grow at a Compound Annual Growth Rate (CAGR) of 10.5% and the immunosuppressants market is forecast to grow at a CAGR of 7.3%, although there are more products in the pipeline for immunosuppressants. Immunostimulatory Monoclonal Antibodies (mAbs) such as cancer antibodies and vaccines will contribute most to the growth of the markets as there is a great deal of scope for these classes in the oncology market, valued at $60.5 billion in 2010.

Antimetabolic Drugs Generated the Highest Revenues of all Classes of Immunomodulators

Antiproliferative and antimetabolic drugs generated revenues of approximately $33.2 billion in 2010. However, with the gradual approval of mAbs as first-line treatment, antiproliferative and antimetabolic drugs will grow at a comparatively slow rate. Conventional therapy, namely chemotherapy, has a long history of poor safety profiles due to systemic action characteristics, which means its often fails to impart the desired effect at the site of action. Cancer is better managed with personalized oncological treatments such as measuring erbB2 (erythroblastic leukemia viral oncogene homolog 2) and EGFR (Epidermal Growth Factor Receptor) proteins in breast, lung and colorectal cancer patients before selecting suitable treatments. Herceptin is used in the treatment of women with breast cancer in which HER2 (Human Epidermal growth factor Receptor 2) protein is overexpressed.

Antibodies Market Forecast to show Highest Growth Rate of all Classes of Immunomodulators

Antibodies were the fastest growing segment in the global immunomodulators market in 2010. The global antibodies market was worth $51.8 billion in 2010, comprising mAbs and fusion proteins. Antibodies are used in a range of oncology indications and autoimmune diseases. In 2010, immunostimulating antibodies generated revenues of $23 billion while immunosuppressive antibodies generated $28.8 billion. MAbs are gradually moving into the treatment of Central Nervous System (CNS) disorders such as Alzheimer's disease and metabolic disorders such as diabetes. The first therapeutic mAb approved by the Food and Drug Administration (FDA) was Muromonab-CD3 (trade name Orthoclone OKT3), a murine IgG2a CD3 specific transplant rejection drug, also known as muromonab. It was approved in 1986 and was used in steroid-resistant solid organ transplant recipients. Since the launch of Orthoclone OKT3 in 1992, 30 mAbs have been launched globally. Of these, three have been discontinued due to safety issues. Successful mAbs such as rituxan, avastin and remicade have received regulatory approvals for multiple indications, further increasing the patient base.

Report Summary

This report provides insights about immunomodulators sales forecasts until 2017.I Immunomodulators markets in the key geographies of the US, Europe and other relevant regions are also covered in the report, as are immunomodulators R&D pipelines. The report provides in-depth analysis and market forecasts of the major drug classes, which include immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, and antimetabolites), and immunostimulants (antibodies, interferon alpha and vaccines). The report also explores the competitive landscape, with a competitive analysis of the top companies in the market.

Report Scope

- Data and analysis of the immunomodulators market in the leading geographies of the US and Europe. Different drug classes of immunomodulators discussed in the report are immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, antimetabolites) and immunostimulants (antibodies, interferon alpha and vaccines).
- Annualized market data for the immunomodulators market from 2002 to 2010, with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes
- Key drivers and restraints that have had significant impact on the market.
- Competitive landscape of the global immunomodulators market including benchmarking of the top companies. The key companies studied in this report are Hoffman La Roche, Amgen, Abbott, Johnson & Johnson, Novartis, Biogen Idec, Merck, Bristol-Myers Squibb, Eli Lilly.

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

£2,235.35	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£4,470.69	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£6,706.04	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£2,235.35	Add to Wishlist
Change Currency	GBP EURO USD

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Immunomodulators Market to 2017 - Market Introduction

2.1 GBI Research Report Guidance

3 Immunomodulators Market to 2017 - Market Characterization

3.1 Classification
3.2 Drivers and Barriers
3.3 Global Immunomodulators Market Drivers
3.4 Global Immunomodulators Market Restraints
3.5 Unmet Needs
3.6 Revenue Forecast - Global

4 Immunomodulators Market to 2017 - Geographical Landscape

4.1 The US
4.2 Europe
4.3 ROW

5 Immunomodulators Market to 2017 - Immunosuppressants

5.1 Introduction
5.2 Drug Classes
5.3 Applications
5.4 Global Market Size

6 Immunosuppressants - Antibodies

6.1 Introduction
6.2 Prescription Population
6.3 Annual Cost of Therapy
6.4 Revenue
6.5 Pipeline Molecules

7 Immunosuppressants - Interferon Beta

7.1 Introduction
7.2 Prescription Population
7.3 Annual Cost of Therapy
7.4 Revenue
7.5 Pipeline Molecules

8 Immunosuppressants - Glucocorticoids

8.1 Introduction
8.2 Therapeutic Indications
8.3 Immunological Mode of Action
8.4 Prescription Population
8.5 Annual Cost of Therapy
8.6 Revenue
8.7 Pipeline Molecules

9 Immunosuppressants - Calcineurin Inhibitors

9.1 Introduction
9.2 Prescription Population
9.3 Annual Cost of Therapy
9.4 Revenue
9.5 Pipeline Molecules

10 Immunosuppressants - Antimetabolites

10.1 Introduction
10.2 Prescription Population
10.3 Annual Cost of Therapy
10.4 Revenue
10.5 Pipeline Molecules

11 Immunomodulators Market to 2017 - Immunostimulants

11.1 Introduction
11.2 Drug Classes
11.3 Applications
11.4 Global Market Size

12 Immunostimulants - Vaccines, Active Immunity

12.1 Introduction
12.2 Target Population
12.3 Revenue
12.4 Pipeline Molecules

13 Immunostimulants: Antibodies - Passive Immunity

13.1 Introduction
13.2 Prescription Population
13.3 Annual Cost of Therapy
13.4 Revenue
13.5 Pipeline Molecules

14 Immunostimulants: Interferon Alpha - Passive Immunity

14.1 Introduction
14.2 Prescription Population
14.3 Annual Cost of Therapy
14.4 Revenue
14.5 Pipeline Molecules

15 Immunomodulators Market to 2017 - Competitive Landscape

15.1 Market Share Analysis
15.2 Hoffmann-La Roche Ltd Roche
15.3 Amgen Inc
15.4 Abbott Laboratories
15.5 Johnson & Johnson
15.6 Novartis AG
15.7 Biogen Idec
15.8 Merck & Co Inc
15.9 Bristol Myers Squibb Company
15.10 Eli Lilly and Company

16 Immunomodulators Market to 2017 - Strategic Consolidations

16.1 M&A Deals by Type
16.2 M&A Landscape
16.3 Major Deals
16.4 Licensing Deals
16.5 Major Deals
16.6 Partnership Deals
16.7 Major Deals

17 Immunomodulators Market to 2017 - Appendix

17.1 Market Definitions
17.2 Abbreviations
17.3 Research Methodology
17.4 Therapeutic Landscape
17.5 Geographical Landscape
17.6 Pipeline Analysis
17.7 Competitive Landscape
17.8 Contact Us
17.9 Disclaimer
17.10 Sources

List of Tables

Table 1: Immunomodulators Market to 2017, Global, Revenue ($bn), 2002-2010
Table 2: Immunomodulators Market to 2017, Global, Revenue Forecasts ($bn), 2010-2017
Table 3: Immunomodulators Market to 2017, Global, Annual Cost of Therapy ($), 2002-2010
Table 4: Immunomodulators Market to 2017, Global, Annual Cost of Therapy ($), 2010-2017
Table 5: Immunomodulators Market to 2017, Global, Prescription Population (million), 2002-2010
Table 6: Immunomodulators Market to 2017, Global, Prescription Population (million), 2010-2017
Table 7: Immunomodulators Market to 2017, The US, Revenue ($bn), 2002-2010
Table 8: Immunomodulators Market to 2017, The US, Revenue Forecasts (bn), 2010-2017
Table 9: Immunomodulators Market to 2017, Europe, Revenue ($bn), 2002-2010
Table 10: Immunomodulators Market to 2017, Europe, Revenue Forecasts ($bn), 2010-2017
Table 11: Immunomodulators Market to 2017, ROW, Revenue ($bn), 2002-2010
Table 12: Immunomodulators Market to 2017, ROW, Revenue Forecasts ($bn), 2010-2017
Table 13: Immunomodulators Market to 2017, Immunosuppressants, Global, Revenue ($bn), 2002-2010
Table 14: Immunomodulators Market to 2017, Immunosuppressants, Global, Revenue Forecasts ($bn), 2010-2017
Table 15: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Prescription Population (million), 2002-2010
Table 16: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Prescription Population (million), 2010-2017
Table 17: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Prescription Population (million), 2002-2010
Table 18: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Prescription Population (million), 2010-2017
Table 19: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Prescription Population (million), 2002-2010
Table 20: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Prescription Population (million), 2010-2017
Table 21: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Prescription Population (million), 2002-2010
Table 22: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Prescription Population (million), 2010-2017
Table 23: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Annual Cost of Therapy ($), 2002-2010
Table 24: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Annual Cost of Therapy ($), 2010-2017
Table 25: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Annual Cost of Therapy ($), 2002-2010
Table 26: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Annual Cost of Therapy ($), 2010-2017
Table 27: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Annual Cost of Therapy ($), 2002-2010
Table 28: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Annual Cost of Therapy ($), 2010-2017
Table 29: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Annual Cost of Therapy ($), 2002-2010
Table 30: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Annual Cost of Therapy ($), 2010-2017
Table 31: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Revenue ($bn), 2002-2010
Table 32: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Revenue Forecasts ($bn), 2010-2017
Table 33: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Revenue ($bn), 2002-2010
Table 34: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Revenue Forecasts ($bn), 2010-2017
Table 35: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Revenue ($bn), 2002-2010
Table 36: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Revenue Forecasts ($bn), 2010-2017
Table 37: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Revenue ($bn), 2002-2010
Table 38: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Revenue Forecasts ($bn), 2010-2017
Table 39: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Phase III, 2011
Table 40: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Phase II, 2011
Table 41: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Phase I, 2011
Table 42: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Preclinical/Discovery Phase, 2011
Table 43: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Prescription Population (million), 2002-2010
Table 44: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Prescription Population (million), 2010-2017
Table 45: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Prescription Population, 2002-2010
Table 46: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Prescription Population, 2010-2017
Table 47: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Prescription Population, 2002-2010
Table 48: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Prescription Population, 2010-2017
Table 49: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Prescription Population, 2002-2010
Table 50: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Prescription Population, 2010-2017
Table 51: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Annual Cost of Therapy ($), 2002-2010
Table 52: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Annual Cost of Therapy ($), 2010-2017
Table 53: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US Annual Cost of Therapy ($), 2002-2010
Table 54: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US Annual Cost of Therapy ($), 2010-2017
Table 55: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Annual Cost of Therapy ($), 2002-2010
Table 56: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Annual Cost of Therapy ($), 2010-2017
Table 57: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Annual Cost of Therapy ($), 2002-2010
Table 58: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Annual Cost of Therapy ($), 2010-2017
Table 59: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Revenue ($bn), 2002-2010
Table 60: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Revenue Forecasts ($bn), 2010-2017
Table 61: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Revenue ($bn), 2002-2010
Table 62: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Revenue Forecasts ($bn), 2010-2017
Table 63: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Revenue ($bn), 2002-2010
Table 64: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Revenue Forecasts ($bn), 2010-2017
Table 65: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Revenue ($bn), 2002-2010
Table 66: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Revenue Forecasts ($bn), 2010-2017
Table 67: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Phase III, 2011
Table 68: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Phase II, 2011
Table 69: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Phase I, 2011
Table 70: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Preclinical/Discovery Phase, 2011
Table 71: Immunomodulators Market to 2017, Comparative Glucocorticoid Potency, 2011
Table 72: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Prescription Population (million), 2002-2010
Table 73: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Prescription Population (million), 2010-2017
Table 74: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Prescription Population (million), 2002-2010
Table 75: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Prescription Population (million), 2010-2017
Table 76: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Prescription Population (million), 2002-2010
Table 77: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Prescription Population (million), 2010-2017
Table 78: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Prescription Population (million), 2002-2010
Table 79: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Prescription Population (million), 2010-2017
Table 80: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Annual Cost of Therapy ($), 2002-2010
Table 81: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Annual Cost of Therapy ($), 2010-2017
Table 82: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Annual Cost of Therapy ($), 2002-2010
Table 83: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Annual Cost of Therapy ($), 2010-2017
Table 84: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Annual Cost of Therapy ($), 2002-2010
Table 85: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Annual Cost of Therapy ($), 2010-2017
Table 86: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Annual Cost of Therapy ($), 2002-2010
Table 87: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Annual Cost of Therapy ($), 2010-2017
Table 88: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Revenue ($bn), 2002-2010
Table 89: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Revenue Forecasts ($bn), 2010-2017
Table 90: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Revenue ($bn), 2002-2010
Table 91: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Revenue Forecasts ($bn), 2010-2017
Table 92: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Revenue ($bn), 2002-2010
Table 93: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Revenue Forecasts ($bn), 2010-2017
Table 94: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Revenue ($bn), 2002-2010
Table 95: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Revenue Forecasts ($bn), 2010-2017
Table 96: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Phase III, 2011
Table 97: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Phase II, 2011
Table 98: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Phase I, 2011
Table 99: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Preclinical/Discovery Phase, 2011
Table 100: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Prescription Population, 2002-2010
Table 101: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Prescription Population, 2010-2017
Table 102: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Prescription Population, 2002-2010
Table 103: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Prescription Population, 2010-2017
Table 104: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Prescription Population, 2002-2010
Table 105: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Prescription Population, 2010-2017
Table 106: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Prescription Population, 2002-2010
Table 107: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Prescription Population, 2010-2017
Table 108: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Annual Cost of Therapy ($), 2002-2010
Table 109: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Annual Cost of Therapy ($), 2010-2017
Table 110: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Annual Cost of Therapy ($), 2002-2010
Table 111: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Annual Cost of Therapy ($), 2010-2017
Table 112: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Annual Cost of Therapy ($), 2002-2010
Table 113: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Annual Cost of Therapy ($), 2010-2017
Table 114: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Annual Cost of Therapy ($), 2002-2010
Table 115: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Annual Cost of Therapy ($), 2010-2017
Table 116: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Revenue ($bn), 2002-2010
Table 117: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Revenue Forecasts ($bn), 2010-2017
Table 118: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Revenue ($bn), 2002-2010
Table 119: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Revenue Forecasts ($bn), 2010-2017
Table 120: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Revenue ($bn), 2002-2010
Table 121: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Revenue Forecasts ($bn), 2010-2017
Table 122: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Revenue ($bn), 2002-2010
Table 123: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Revenue Forecasts ($bn), 2010-2017
Table 124: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Phase III, 2011
Table 125: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Phase II, 2011
Table 126: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Phase I, 2011
Table 127: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Preclinical/Discovery Phase, 2011
Table 128: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Prescription Population (million), 2002-2010
Table 129: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Prescription Population (million), 2010-2017
Table 130: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Prescription Population (million), 2002-2010
Table 131: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Prescription Population (million), 2010-2017
Table 132: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Prescription Population (million), 2002-2010
Table 133: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Prescription Population (million), 2010-2017
Table 134: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Prescription Population (million), 2002-2010
Table 135: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Prescription Population (million), 2010-2017
Table 136: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Annual Cost of Therapy ($), 2002-2010
Table 137: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Annual Cost of Therapy ($), 2010-2017
Table 138: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Annual Cost of Therapy ($), 2002-2010
Table 139: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Annual Cost of Therapy ($), 2010-2017
Table 140: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Annual Cost of Therapy ($), 2002-2010
Table 141: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Annual Cost of Therapy ($), 2010-2017
Table 142: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Annual Cost of Therapy ($), 2002-2010
Table 143: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Annual Cost of Therapy ($), 2010-2017
Table 144: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Revenue ($bn), 2002-2010
Table 145: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Revenue Forecasts ($bn), 2010-2017
Table 146: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Revenue ($bn), 2002-2010
Table 147: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Revenue Forecasts ($bn), 2010-2017
Table 148: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Revenue ($bn), 2002-2010
Table 149: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Revenue Forecasts ($bn), 2010-2017
Table 150: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Revenue ($bn), 2002-2010
Table 151: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Revenue Forecasts ($bn), 2010-2017
Table 152: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Phase III, 2011
Table 153: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Phase II, 2011
Table 154: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Phase I, 2011
Table 155: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Preclinical/Discovery Phase, 2011
Table 156: Immunomodulators Market to 2017, Immunostimulants, Revenue ($bn), 2002-2010
Table 157: Immunomodulators Market to 2017, Immunostimulants, Revenue Forecasts ($bn), 2010-2017
Table 158: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Vaccine Preventable Disease, 2010
Table 159: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Target Pediatric and Adult Population ('000), 2002-2010
Table 160: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Target Pediatric and Adult Population ('000), 2010-2017
Table 161: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Revenue ($bn), 2002-2010
Table 162: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Revenue Forecasts ($bn), 2010-2017
Table 163: Immunomodulators Market to 2017, Immunostimulants, Vaccines, The US, Revenue ($bn), 2002-2010
Table 164: Immunomodulators Market to 2017, Immunostimulants, Vaccines, The US, Revenue Forecasts ($bn), 2010-2017
Table 165: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Europe, Revenue ($bn), 2002-2010
Table 166: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Europe, Revenue Forecasts ($bn), 2010-2017
Table 167: Immunomodulators Market to 2017, Immunostimulants, Vaccines, ROW, Revenue ($bn), 2002-2010
Table 168: Immunomodulators Market to 2017, Immunostimulants, Vaccines, ROW, Revenue Forecasts ($bn), 2010-2017
Table 169: Immunomodulators Market to 2017, Immunostimulants, Vaccines, NDA Filed Molecules, 2011
Table 170: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Phase III, 2011
Table 171: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Phase II, 2011
Table 172: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Phase I, 2011
Table 173: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Preclinical/Discovery Phase, 2011
Table 174: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Prescription Population (million), 2002-2010
Table 175: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Prescription Population (million), 2010-2017
Table 176: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Prescription Population (million), 2002-2010
Table 177: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Prescription Population (million), 2010-2017
Table 178: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Prescription Population (million), 2002-2010
Table 179: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Prescription Population (million), 2010-2017
Table 180: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Prescription Population (million), 2002-2010
Table 181: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Prescription Population (million), 2010-2017
Table 182: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Annual Cost of Therapy ($), 2002-2010
Table 183: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Annual Cost of Therapy ($), 2010-2017
Table 184: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Annual Cost of Therapy ($), 2002-2010
Table 185: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Annual Cost of Therapy ($), 2010-2017
Table 186: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Annual Cost of Therapy ($), 2002-2010
Table 187: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Annual Cost of Therapy ($), 2010-2017
Table 188: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Annual Cost of Therapy ($), 2002-2010
Table 189: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Annual Cost of Therapy ($), 2010-2017
Table 190: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Revenue ($bn), 2002-2010
Table 191: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Revenue Forecasts ($bn), 2010-2017
Table 192: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Revenue ($bn), 2002-2010
Table 193: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Revenue Forecasts ($bn), 2010-2017
Table 194: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Revenue ($bn), 2002-2010
Table 195: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Revenue Forecasts ($bn), 2010-2017
Table 196: Immunomodulators Market to 2017, Immunostimulants, I Antibodies, ROW, Revenue ($bn), 2002-2010
Table 197: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Revenue Forecasts ($bn), 2010-2017
Table 198: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, NDA Filed, 2011
Table 199: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Phase III, 2011
Table 200: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Phase II, 2011
Table 201: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Phase I, 2011
Table 202: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Preclinical/Discovery Phase, 2011
Table 203: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Pharmaceutical Forms of Interferons, 2011
Table 204: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Prescription Population, 2002-2010
Table 205: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Prescription Population, 2010-2017
Table 206: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Prescription Population, 2002-2010
Table 207: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Prescription Population, 2010-2017
Table 208: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Prescription Population, 2002-2010
Table 209: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Prescription Population, 2010-2017
Table 210: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue ($bn), 2002-2010
Table 211: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue Forecasts ($bn), 2010-2017
Table 212: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Annual Cost of Therapy ($), 2002-2010
Table 213: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Annual Cost of Therapy ($), 2010-2017
Table 214: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Annual Cost of Therapy ($), 2002-2010
Table 215: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Annual Cost of Therapy ($), 2010-2017
Table 216: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Annual Cost of Therapy ($), 2002-2010
Table 217: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Annual Cost of Therapy ($), 2010-2017
Table 218: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Annual Cost of Therapy ($), 2002-2010
Table 219: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Annual Cost of Therapy ($), 2010-2017
Table 220: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Revenue ($bn), 2002-2010
Table 221: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Revenue Forecasts ($bn), 2010-2017
Table 222: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Revenue ($bn), 2002-2010
Table 223: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Revenue Forecasts ($bn), 2010-2017
Table 224: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Revenue ($bn), 2002-2010
Table 225: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Revenue Forecasts ($bn), 2010-2017
Table 226: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue ($m), 2002-2010
Table 227: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue Forecasts ($m), 2010-2017
Table 228: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Phase III, 2011
Table 229: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Phase II, 2011
Table 230: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Phase I, 2011
Table 231: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Preclinical/Discovery Phase, 2011
Table 232: Immunomodulators Market to 2017, Roche, Marketed Products, Sales ($m), 2010
Table 233: Immunomodulators Market to 2017, Amgen Inc, Marketed Products, Sales ($m), 2010
Table 234: Immunomodulators Market to 2017, Abbott Laboratories, Marketed Products, Sales ($m), 2010
Table 235: Immunomodulators Market to 2017, Johnson & Johnson, Marketed Products, Sales ($m), 2010
Table 236: Immunomodulators Market to 2017, Novartis AG, Marketed Products, Sales ($m) 2010
Table 237: Immunomodulators Market to 2017, Biogen Idec, Marketed Products, Sales ($m), 2010
Table 238: Immunomodulators Market to 2017, Merck & Co Inc, Marketed Products, Sales ($m), 2010
Table 239: Immunomodulators Market to 2017, Bristol-Myers Squibb Company, Marketed Products, Sales ($m), 2010
Table 240: Immunomodulators Market to 2017, Eli Lilly and Company, Marketed Products, Sales ($m), 2010
Table 241: Immunomodulators Market to 2017, Global, Strategic Consolidations, M&A by Year, 2010-2011
Table 242: Immunomodulators Market to 2017, Global, Strategic Consolidations, Top Five M&A Deals by Value, 2010-2011

Visitor Comments

All Comments

Change Currency

GBP

EURO

USD

Last Viewed

Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017

Healthcare Industry in United States

Nam Tai Electronics Inc (NTE) - Investment Research

MKS Instruments Inc (MKSI) - Investment Research

LeCROY Corporation (LCRY) - Investment Research

Healthcare and Medical Company Profiles

Healthcare and Medical Company Profiles contain up to date financial, strategic, operational, SWOT analysis and product information on the activities of thousands of healthcare and medical companies.

Become an Affiliate

Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?

Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website. If a sale is made from your visitor, you earn commission (a fixed percentage of the price of a product).

Custom Research

Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.

Healthcare and Medical	Type	Keywords Phrase All Words Any Word
Microsoft Windows users can hold the CTRL Key to select more than one sector or country at a time. Apple users can hold the CMD Key to do the same.	Country	Industry Sector
Publisher	Order By Relevance Date	Published In

Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017

Select License Type

Immunosuppressants hold a 64% market share of the immunomodulators market

Speak to an Advisor

Select License Type

Table of Contents

Visitor Comments

Change Currency

Last Viewed

Healthcare and Medical Company Profiles

Become an Affiliate

Custom Research

News

Market Insights

Companies And Markets

Customer Support

Corporate Accounts

Contact Details

Contrast settings

Text size settings

All
Afghanistan
Africa
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua and Barbuda
Argentina
Armenia
Aruba
Asia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia-Herzegovina
Botswana
Bouvet Island
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Caribbean
Cayman Islands
Central African Republic
Central America
Central Europe
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Conch Republic
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Democratic Republic of Congo
Denmark
Djibouti
Dominica
Dominican Republic
Eastern Europe
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Europe
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Global
Greece
Greenland
Grenada
Guadeloupe (French)
Guam (USA)
Guatemala
Guernsey
Guinea
Guinea Bissau
Guyana
Haiti
Heard Island and McDonald Islans
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote D`Ivoire)
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kurdistan
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique (French)
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Middle East
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia (French)
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North America
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Island
Poland
Polynesia (French)
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russia
Rwanda
Saint Barthelemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Scandinavia
Schengen countries
Senegal
Serbia and Montenegro
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South America
South Georgia and the South Sandwich Islands
South Korea
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste (East Timor)
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Virgin Islands
Wallis and Futuna Islands
Western Sahara
Yemen
Zambia
Zimbabwe

All
Aerospace
Agriculture, Farming & Raw Materials
Automotive and Parts
Business Services
Chemicals
Construction
Consumer Goods
Defence
Energy and Utilities
Environmental
Finance and Banking
Food and Drink
Healthcare and Medical
Industrial
Information Technology
Leisure
Logistics
Media
Paper and Packaging
Publishing and Printing
Real Estate
Retail
Security
Telecommunications
Textiles and Clothing
Transportation
Travel